Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 2/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 3/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
| ▸ | CCR5 | P51681 | 1/20 | 0.37 |
| ▸ | PTPRB | P23467 | 1/20 | 0.37 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.37 |
| ▸ | STS | P08842 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | HPGDS | O60760 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | ABL2 | P42684 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31626148 | 1.00 | JAK1 (0.42) | JAK1JAK2SRCEGFRHTR6 | |
| SCHEMBL15171143 | 0.94 | JAK2 (0.49) | JAK1JAK2SRCEGFRHTR6 | |
| SCHEMBL15711178 | 0.94 | JAK2 (0.49) | JAK1JAK2SRCEGFRHTR6 | |
| SCHEMBL15171260 | 0.93 | HTR6 (0.46) | JAK1JAK2SRCEGFRHTR6 | |
| SCHEMBL16341186 | 0.93 | HTR6 (0.46) | JAK1JAK2SRCEGFRHTR6 | |
| SCHEMBL20480936 | 0.91 | JAK1 (0.39) | JAK1JAK2SRCEGFRHTR6 | |
| SCHEMBL30760762 | 0.89 | JAK2 (0.44) | JAK1JAK2SRCEGFRHTR6 | |
| SCHEMBL30760906 | 0.89 | JAK2 (0.44) | JAK1JAK2SRCEGFRHTR6 | |
| SCHEMBL30760777 | 0.89 | JAK2 (0.44) | JAK1JAK2SRCEGFRHTR6 | |
| SCHEMBL30760907 | 0.89 | JAK2 (0.44) | JAK1JAK2SRCEGFRHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240083899-A1 | PURINONE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2024-03-14 | — | — | US | disclosed |
| EP-3590938-B1 | PURINONE DERIVATIVE AS BTK KINASE INHIBITOR | ONO PHARMACEUTICAL CO (JP) | 2023-05-24 | — | — | EP | disclosed |
| US-20220363684-A1 | PURINONE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2022-11-17 | — | — | US | disclosed |
| US-20200048256-A1 | PURINONE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-02-13 | — | — | US | disclosed |
| EP-3112368-B1 | PURINONE DERIVATIVE AS BTK KINASE INHIBITOR | ONO PHARMACEUTICAL CO (JP) | 2020-02-12 | — | — | EP | disclosed |
| US-20190169192-A1 | PURINONE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-06-06 | — | — | US | disclosed |
| US-10233185-B2 | Purinone derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-03-19 | — | — | US | disclosed |
| US-20180170933-A1 | PURINONE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-06-21 | — | — | US | disclosed |
| US-9926322-B2 | Purinone derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-03-27 | — | — | US | disclosed |
| US-9879013-B2 | Purinone derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-01-30 | — | — | US | disclosed |
| US-20170313705-A1 | PURINONE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-11-02 | — | — | US | disclosed |
| US-9732082-B2 | — | — | 2017-08-15 | — | — | US | disclosed |
| EP-3112368-A1 | PURINONE DERIVATIVE AS BTK KINASE INHIBITOR | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-01-04 | — | — | EP | disclosed |
| EP-2578585-B1 | PURINONE DERIVATIVE AS BTK KINASE INHIBITOR | ONO PHARMACEUTICAL CO (JP) | 2016-07-20 | — | — | EP | disclosed |
| US-20150094299-A1 | PURINONE DERIVATIVE | ONO PHARMACEUTICAL CO (JP) | 2015-04-02 | — | — | US | disclosed |
| US-8940725-B2 | Purinone derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-01-27 | — | — | US | disclosed |
| US-8557803-B2 | Purinone derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-10-15 | — | — | US | disclosed |
| US-20130217880-A1 | PURINONE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-08-22 | — | — | US | disclosed |
| EP-2578585-A1 | PURINONE DERIVATIVE | ONO Pharmaceutical Co., Ltd. (JP) | 2013-04-10 | — | — | EP | disclosed |
| US-20130079327-A1 | PURINONE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169192-A1 | PURINONE DERIVATIVE | BTK, KIT, SYK | JAK1 35/4885JAK2 15/4885SRC 212/4885 |
| US-20130217880-A1 | PURINONE DERIVATIVE | BTK, KIT, SYK | JAK1 35/4885JAK2 15/4885SRC 212/4885 |
| US-20130079327-A1 | PURINONE DERIVATIVE | BTK, KIT, SYK | JAK1 35/4885JAK2 15/4885SRC 212/4885 |
| US-10233185-B2 | Purinone derivative | BTK, KIT, SYK | JAK1 35/4885JAK2 15/4885SRC 212/4885 |
| US-20150094299-A1 | PURINONE DERIVATIVE | BTK, KIT, SYK | JAK1 35/4885JAK2 15/4885SRC 212/4885 |
| US-20200048256-A1 | PURINONE DERIVATIVE | BTK, KIT, SYK | JAK1 35/4885JAK2 15/4885SRC 212/4885 |
| US-20220363684-A1 | PURINONE DERIVATIVE | BTK, KIT, SYK | JAK1 35/4885JAK2 15/4885SRC 212/4885 |
| US-20180170933-A1 | PURINONE DERIVATIVE | BTK, KIT, SYK | JAK1 35/4885JAK2 15/4885SRC 212/4885 |
| US-20170313705-A1 | PURINONE DERIVATIVE | BTK, KIT, SYK | JAK1 35/4885JAK2 15/4885SRC 212/4885 |
| US-20240083899-A1 | PURINONE DERIVATIVE | BTK, KIT, SYK | JAK1 35/4885JAK2 15/4885SRC 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.